Cargando…
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells
BACKGROUND: Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2 therapies. However, recent analyses of clinical trial data have foun...
Autores principales: | Huang, Yao, Burns, David J., Rich, Benjamin E., MacNeil, Ian A., Dandapat, Abhijit, Soltani, Sajjad M., Myhre, Samantha, Sullivan, Brian F., Lange, Carol A., Furcht, Leo T., Laing, Lance G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356237/ https://www.ncbi.nlm.nih.gov/pubmed/28302091 http://dx.doi.org/10.1186/s12885-017-3181-0 |
Ejemplares similares
-
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity
por: Huang, Yao, et al.
Publicado: (2016) -
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020) -
Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
por: MacNeil, Ian A., et al.
Publicado: (2022) -
Diminished Functional Role and Altered Localization of Shp2 in Non-Small Cell Lung Cancer Cells With Egfr-Activating Mutations
por: Furcht, Christopher M., et al.
Publicado: (2012) -
Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells
por: Rojhannezhad, Mahdieh, et al.
Publicado: (2023)